Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00226668
Status:
WITHDRAWN
Last Update Posted:
2008-01-03
First Post:
2005-09-23
Brief Title:
XERECEPT hCRF for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema
Sponsor:
Celtic Pharma Development Services
Organization:
Celtic Pharma Development Services
Study Overview
Official Title:
A Phase III Randomized Double-Blind Study Comparing Human Corticotropin-Releasing Factor hCRF to Dexamethasone for Control of Symptoms Associated With Peritumoral Brain Edema in Patients With Primary Malignant Glioma
Status:
WITHDRAWN
Status Verified Date:
2007-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Alternate study projected to assess imaging endpoints versus clinical endpoints
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to examine the safety and efficacy of XERECEPT human Corticotropin-Releasing Factor or hCRF compared to dexamethasone in patients with primary malignant glioma who require increased dexamethasone doses to control symptom of peritumoral brain edema
Detailed Description:
XERECEPT is not a potential treatment for cancer but may reduce the edema associated with tumors and as a result decrease neurological symptoms
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| corticorelin acetate injection | None | None | None |